<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title>PLoS ONE</journal-title><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">07-PONE-RA-02449R1</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0001462</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Genetics and Genomics/Genetics of Disease</subject><subject>Cardiovascular Disorders/Coronary Artery Disease</subject><subject>Cardiovascular Disorders/Myocardial Infarction</subject></subj-group></article-categories><title-group><article-title>The P2Y<sub>13</sub> Met-158-Thr Polymorphism, Which Is in Linkage Disequilibrium with the P2Y<sub>12</sub> Locus, Is Not Associated with Acute Myocardial Infarction</article-title><alt-title alt-title-type="running-head">P2Y12 Polymorphisms and AMI</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Amisten</surname><given-names>Stefan</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Braun</surname><given-names>Oscar &#x000d6;.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Johansson</surname><given-names>Lovisa</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ridderstr&#x000e5;le</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Melander</surname><given-names>Olle</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Erlinge</surname><given-names>David</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Department of Cardiology, Lund University Hospital, Lund, Sweden</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Department of Clinical Sciences, Lund University, Malm&#x000f6;, Sweden</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Kronenberg</surname><given-names>Florian</given-names></name><role>Academic Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">Innsbruck Medical University, Austria</aff><author-notes><corresp id="cor1">&#x0002a; To whom correspondence should be addressed. E-mail: <email>david.erlinge@med.lu.se</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: OM DE SA. Performed the experiments: LJ SA. Analyzed the data: OM LJ DE SA OB MR. Contributed reagents/materials/analysis tools: OM DE MR. Wrote the paper: OM LJ DE SA OB MR.</p></fn></author-notes><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>23</day><month>1</month><year>2008</year></pub-date><volume>3</volume><issue>1</issue><elocation-id>e1462</elocation-id><history><date date-type="received"><day>9</day><month>10</month><year>2007</year></date><date date-type="accepted"><day>22</day><month>12</month><year>2007</year></date></history><copyright-statement>Amisten et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement><copyright-year>2008</copyright-year><abstract><sec><title>Background and Aims</title><p>The aims of this study were to investigate (1) if P2Y<sub>12</sub> polymorphisms defining the P2Y<sub>12</sub> H2 allele are associated with any other SNPs that may explain the previously reported association with increased ADP induced platelet activation and association with peripheral arterial disease and coronary artery disease and (2) if such variants are associated with acute myocardial infarction (AMI) or classical risk factors for AMI.</p></sec><sec sec-type="methods"><title>Methods and Results</title><p>The P2Y<sub>13</sub> Met-158-Thr polymorphism was found to be in linkage disequilibrium (LD) with the P2Y<sub>12</sub> H2 haplotype (all examined SNPs: D&#x02032;&#x0200a;&#x0003d;&#x0200a;1.0, r<sup>2</sup>&#x0200a;&#x0003d;&#x0200a;0.936&#x02013;1.0), defining a novel P2Y<sub>12</sub> H2/P2Y<sub>13</sub> Thr-158 haplotype. Genotyping of an AMI case control population (n&#x0200a;&#x0003d;&#x0200a;1244 cases, 2488 controls) revealed no association of the P2Y<sub>13</sub> Thr-158 allele with AMI (OR&#x0200a;&#x0003d;&#x0200a;0.96, 95&#x00025; C.I. 0.82&#x02013;1.12, P&#x0200a;&#x0003d;&#x0200a;0.63). Also, no differences between the genotype frequencies of P2Y<sub>13</sub> Met-158-Met and Met-158-Thr/Thr-158-Thr were seen in AMI case-control subpopulations (early onset AMI OR&#x0200a;&#x0003d;&#x0200a;1.06, 95&#x00025; C.I. 0.85&#x02013;1.31, P&#x0200a;&#x0003d;&#x0200a;0.62); family history of AMI (OR&#x0200a;&#x0003d;&#x0200a;0.98, 95&#x00025; C.I. 0.78&#x02013;1.22, P&#x0200a;&#x0003d;&#x0200a;0.83) nor in early onset AMIs with family history of AMI (OR&#x0200a;&#x0003d;&#x0200a;1.0, 95&#x00025; C.I. 0.74&#x02013;1.36, P&#x0200a;&#x0003d;&#x0200a;1.0). Genotyping of the P2Y<sub>13</sub> Met-158-Thr polymorphism in a population based sample (n&#x0200a;&#x0003d;&#x0200a;6055) revealed no association with cardiovascular risk factors. In addition, the P2Y<sub>13</sub> Met-158-Thr polymorphism was genotyped in a diabetes case-control population, and associations were found neither with DM nor with any examined DM risk factors.</p></sec><sec><title>Conclusion Genotyping</title><p>The P2Y<sub>13</sub> Met-158-Thr polymorphism is in tight LD with the P2Y<sub>12</sub> locus but is not associated with AMI or classical cardiovascular risk factors.</p></sec></abstract><counts><page-count count="6"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Three human adenosine diphosphate (ADP) receptors have been cloned: P2Y<sub>1</sub>, P2Y<sub>12</sub> and P2Y<sub>13</sub><xref ref-type="bibr" rid="pone.0001462-Hollopeter1">&#x0005b;1&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0001462-Communi1">&#x0005b;4&#x0005d;</xref>. On platelets, P2Y<sub>1</sub> and P2Y<sub>12</sub> mediate ADP-induced platelet activation and aggregation <xref ref-type="bibr" rid="pone.0001462-Murugappa1">&#x0005b;5&#x0005d;</xref>. In red blood cells, activation of P2Y<sub>13</sub> by the adenosine triphosphate (ATP) metabolite ADP activates a negative feedback loop that inhibits ATP release from erythrocytes <xref ref-type="bibr" rid="pone.0001462-Wang1">&#x0005b;6&#x0005d;</xref>. Rare mutations in the P2Y<sub>12</sub> gene that disrupt P2Y<sub>12</sub> receptor function result in compromised ADP-induced platelet activation and increased bleeding times <xref ref-type="bibr" rid="pone.0001462-Hollopeter1">&#x0005b;1&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0001462-Cattaneo1">&#x0005b;7&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0001462-Remijn1">&#x0005b;8&#x0005d;</xref>.</p><p>The clinical importance of the P2Y<sub>12</sub> receptor as a mediator of platelet activation has become evident in several large-scale clinical studies and inhibition of the P2Y<sub>12</sub> receptor with clopidogrel is one of the cornerstones in treatment and prevention of acute coronary syndromes <xref ref-type="bibr" rid="pone.0001462-Bertrand1">&#x0005b;9&#x0005d;</xref>. Even greater P2Y12 inhibition by prasugrel was recently shown to be even more effective in preventing ischemic events than the standard regimen of clopidogrel <xref ref-type="bibr" rid="pone.0001462-Wiviott1">&#x0005b;10&#x0005d;</xref>.</p><p>A group of single nucleotide polymorphisms (SNPs) in the P2Y<sub>12</sub> gene, forming the so called P2Y<sub>12</sub> H2 haplotype <xref ref-type="bibr" rid="pone.0001462-Fontana1">&#x0005b;11&#x0005d;</xref>, have been associated with increased platelet responsiveness to ADP and increased risk of peripheral arterial disease (PAD) <xref ref-type="bibr" rid="pone.0001462-Fontana1">&#x0005b;11&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0001462-Ziegler1">&#x0005b;13&#x0005d;</xref>. Recently, Cavallari <italic>et al</italic> showed an association of the P2Y12 H2 haplotype with coronary artery disease (CAD) <xref ref-type="bibr" rid="pone.0001462-Cavallari1">&#x0005b;14&#x0005d;</xref>. It has also been proposed that this haplotype may account for variations in response to clopidogrel. However, several studies have failed to confirm any association between platelet function and the H2 haplotype <xref ref-type="bibr" rid="pone.0001462-Cuisset1">&#x0005b;15&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0001462-vonBeckerath1">&#x0005b;17&#x0005d;</xref>.</p><p>The group of polymorphisms that make up the P2Y<sub>12</sub> H2 haplotype are all synonymous polymorphisms that do not change the amino acid sequence of the P2Y<sub>12</sub> protein, and no mechanistic explanation to the reported increased platelet reactivity to ADP associated with this haplotype has been presented <xref ref-type="bibr" rid="pone.0001462-Fontana1">&#x0005b;11&#x0005d;</xref>. However, a non-synonymous polymorphism, Met-158-Thr, in the neighboring P2Y<sub>13</sub> gene, located only 8 kb away from P2Y<sub>12</sub>, could be in linkage disequilibrium with the P2Y<sub>12</sub> H2 haplotype. We hypothesized that the P2Y<sub>13</sub> Met-158-Thr polymorphism of the P2Y<sub>13</sub> receptor could account for the reported effects of the P2Y<sub>12</sub> H2 haplotype since the receptors share the same ligand, ADP. The P2Y<sub>13</sub> receptor has been found on red blood cells and inflammatory cells, both cell types known to interact with platelets <xref ref-type="bibr" rid="pone.0001462-Communi1">&#x0005b;4&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0001462-Wang1">&#x0005b;6&#x0005d;</xref>. The first objective of this study was to examine possible linkage disequilibrium (LD) between the P2Y<sub>12</sub> H2 haplotype and the P2Y<sub>13</sub> Met-158-Thr polymorphism. After showing that this was the case, we aimed at investigating if the P2Y<sub>13</sub> Met-158-Thr polymorphism is associated with acute myocardial infarction (AMI) or diabetes mellitus, two diseases strongly associated with peripheral arterial disease <xref ref-type="bibr" rid="pone.0001462-Lee1">&#x0005b;18&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0001462-Criqui1">&#x0005b;19&#x0005d;</xref>. Our hypothesis that the P2Y<sub>12</sub> H2 haplotype and SNPs in LD with the P2Y<sub>12</sub> H2 haplotype would be associated with AMI was strengthened further by a report linking the P2Y<sub>12</sub> H2 haplotype with coronary artery disease (CAD) <xref ref-type="bibr" rid="pone.0001462-Cavallari1">&#x0005b;14&#x0005d;</xref>, since myocardial infarction is the major complication of CAD <xref ref-type="bibr" rid="pone.0001462-McCullough1">&#x0005b;20&#x0005d;</xref>. In order to do so, the Met-158-Thr polymorphism was genotyped in more than 10,000 individuals divided in three study populations: two sub-populations of the Malm&#x000f6; Diet and Cancer study (an AMI case-control population and a large population with cardiovascular risk factor data <xref ref-type="bibr" rid="pone.0001462-Amisten1">&#x0005b;21&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0001462-Manjer1">&#x0005b;22&#x0005d;</xref>) and a diabetes mellitus case-control population with data on several DM risk factors <xref ref-type="bibr" rid="pone.0001462-OrhoMelander1">&#x0005b;23&#x0005d;</xref>.</p></sec><sec sec-type="materials|methods" id="s2"><title>Materials and Methods</title><sec id="s2a"><title>Malm&#x000f6; diet and cancer population (MDC)</title><p>The study population is made up of 28098 randomly selected men (born 1923&#x02013;1945) and women (born 1923&#x02013;1950) living in the Swedish city of Malm&#x000f6; (population 250 000). Overall participation rate in the study was 41&#x00025;.</p><p>A baseline examination was performed between 1991&#x02013;1996, including assessment of dietary habits, a questionnaire on socio-economic, demographic and lifestyle factors, heredity, medication and previous and current diseases. Blood samples were taken and DNA, lymphocytes, granulocytes, erythrocytes and plasma/serum were stored in a biological bank <xref ref-type="bibr" rid="pone.0001462-Amisten1">&#x0005b;21&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0001462-Manjer1">&#x0005b;22&#x0005d;</xref>.</p></sec><sec id="s2b"><title>AMI Case control population</title><p>On 31 December 2000 the study population was matched with the Swedish National Board of Health and Welfare's National Patient Registry and Cause of Death Registry. AMI cases (first AMI) were identified using the diagnosis criteria defined by the International Classification of Diseases, 9<sup>th</sup> and 10<sup>th</sup> and Revision, Clinical Modification (ICD 9 and 10); ICD 9 codes 410 in the Swedish Patient Registry or 410-414 in the Swedish Cause of death Registry; ICD 10 codes I21 in the Swedish Patient Registry and I21-I25 in the Swedish Cause of Death Registry.</p><p>Two gender- and age (&#x000b1;1 year) -matched AMI-free controls from the MDC population were assigned to each AMI case, resulting in a case-control material consisting of 1244 AMI cases and 2488 AMI-free controls. The myocardial infarction group was then further subdivided into early onset AMIs (EO, <italic>n</italic>&#x0200a;&#x0003d;&#x0200a;622), age at first AMI event &#x0003c;62.8 years (median age of all first event AMI cases) and late onset AMIs (LO, <italic>n</italic>&#x0200a;&#x0003d;&#x0200a;622, age at first AMI event &#x0003e;62.8 years). Family history AMIs (FH, <italic>n</italic>&#x0200a;&#x0003d;&#x0200a;611) were defined as AMI cases where at least one blood related first degree family member had suffered an AMI, and non familial AMIs (<italic>n</italic>&#x0200a;&#x0003d;&#x0200a;633) as cases without any first degree family history of AMI. 319 cases had both early onset and family history AMI (<xref ref-type="table" rid="pone-0001462-t001">table 1</xref>). DNA was available from all cases and controls (<italic>n</italic>&#x0200a;&#x0003d;&#x0200a;3732).</p><table-wrap id="pone-0001462-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0001462.t001</object-id><label>Table 1</label><caption><title>Baseline characteristics of the AMI case control population and cardiovascular group population used for genotyping of the P2Y<sub>13</sub> Thr-158 polymorphism.</title></caption><graphic id="pone-0001462-t001-1" xlink:href="pone.0001462.t001"/><table frame="hsides" rules="groups" alternate-form-of="pone-0001462-t001-1"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Controls (n&#x0200a;&#x0003d;&#x0200a;2488)</td><td align="left" rowspan="1" colspan="1">All AMI cases (n&#x0200a;&#x0003d;&#x0200a;1244)</td><td align="left" rowspan="1" colspan="1">Early onset AMI&#x0002a; (n&#x0200a;&#x0003d;&#x0200a;622)</td><td align="left" rowspan="1" colspan="1">Family history AMI&#x0002a; (n&#x0200a;&#x0003d;&#x0200a;611)</td><td align="left" rowspan="1" colspan="1">Early onset and Family history AMI&#x0002a; (n&#x0200a;&#x0003d;&#x0200a;319)</td><td align="left" rowspan="1" colspan="1">Cardiovascular group (n&#x0200a;&#x0003d;&#x0200a;6055)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="left" rowspan="1" colspan="1">62.5&#x000b1;6.5</td><td align="left" rowspan="1" colspan="1">62.3&#x000b1;6.5</td><td align="left" rowspan="1" colspan="1">59.0&#x000b1;6.3</td><td align="left" rowspan="1" colspan="1">62.5&#x000b1;6.5</td><td align="left" rowspan="1" colspan="1">58.9&#x000b1;6.3</td><td align="left" rowspan="1" colspan="1">57.5&#x000b1;5.9</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex (&#x00025; male)</td><td align="left" rowspan="1" colspan="1">74</td><td align="left" rowspan="1" colspan="1">74</td><td align="left" rowspan="1" colspan="1">79</td><td align="left" rowspan="1" colspan="1">69</td><td align="left" rowspan="1" colspan="1">75</td><td align="left" rowspan="1" colspan="1">42</td></tr><tr><td align="left" rowspan="1" colspan="1">Systolic blood pressure (mmHg)</td><td align="left" rowspan="1" colspan="1">147&#x000b1;20</td><td align="left" rowspan="1" colspan="1">150&#x000b1;21</td><td align="left" rowspan="1" colspan="1">145&#x000b1;19</td><td align="left" rowspan="1" colspan="1">150&#x000b1;20</td><td align="left" rowspan="1" colspan="1">145&#x000b1;19</td><td align="left" rowspan="1" colspan="1">141&#x000b1;19</td></tr><tr><td align="left" rowspan="1" colspan="1">Diastolic blood pressure (mmHg)</td><td align="left" rowspan="1" colspan="1">87.4&#x000b1;10</td><td align="left" rowspan="1" colspan="1">88.5&#x000b1;10</td><td align="left" rowspan="1" colspan="1">87.3&#x000b1;10</td><td align="left" rowspan="1" colspan="1">87.9&#x000b1;10</td><td align="left" rowspan="1" colspan="1">86.8&#x000b1;10</td><td align="left" rowspan="1" colspan="1">87.0&#x000b1;9.5</td></tr><tr><td align="left" rowspan="1" colspan="1">Body Mass Index (kg/m<sup>2</sup>)</td><td align="left" rowspan="1" colspan="1">26.1&#x000b1;3.7</td><td align="left" rowspan="1" colspan="1">26.9&#x000b1;4.0</td><td align="left" rowspan="1" colspan="1">26.9&#x000b1;3.9</td><td align="left" rowspan="1" colspan="1">27.0&#x000b1;4.0</td><td align="left" rowspan="1" colspan="1">26.9&#x000b1;4.0</td><td align="left" rowspan="1" colspan="1">25.9&#x000b1;4.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Current smokers (&#x00025;)</td><td align="left" rowspan="1" colspan="1">27</td><td align="left" rowspan="1" colspan="1">34</td><td align="left" rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1">32</td><td align="left" rowspan="1" colspan="1">37</td><td align="left" rowspan="1" colspan="1">28</td></tr></tbody></table><table-wrap-foot><fn id="nt101"><p>The 1244 AMI cases can be subdivided into three AMI subgroups: early onset AMI, defined as AMI occurring earlier than median age for all AMI cases, family history AMI, where at least one blood related family member also has suffered a myocardial infarction and early onset AMI with family history of AMI. Data of known cardiovascular risk factors was collected in the cardiovascular group only. &#x0002a; subgroups of all AMI cases.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2c"><title>Cardiovascular group population</title><p>Of the MDC, 6103 individuals were randomly selected into a &#x0201c;Cardiovascular cohort&#x0201d; (MDC-CV), a sample thus being representative of MDC, in whom cardiovascular risk factors were measured, including systolic blood pressure, smoking status and anthropometric data and, in the majority (n&#x0200a;&#x0003d;&#x0200a;5540), fasting plasma analyses of glucose, lipids and C-reactive protein (CRP). DNA for genotyping was obtained from 6055 of the 6101 selected individuals.</p></sec><sec id="s2d"><title>Diabetes mellitus case-control population</title><p>The diabetes mellitus case control material has been described elsewhere <xref ref-type="bibr" rid="pone.0001462-OrhoMelander1">&#x0005b;23&#x0005d;</xref>. Briefly, all study subjects originate from the Botnia region in Western Finland and the Helsinki area and age- and gender matched controls were assigned to all type 2 diabetes cases. The case group is composed of 307 unrelated randomly selected individuals with type 2 diabetes (146 males and 161 females, mean age 61 (55&#x02013;67) years, mean BMI 28.7 (26.0&#x02013;31.7)). The control group consisted of 307 unrelated individuals with confirmed normal oral glucose tolerance and without a family history of diabetes (146 males and 161 females, mean age 60 (53&#x02013;67) years, BMI 26.4 (24.1&#x02013;29.2)).</p></sec><sec id="s2e"><title>Extent of H2 haplotype linkage disequilibrium and genotyping of case-control and cardiovascular group populations</title><p>Using HapMap and the Human Genome assembly build 36.2, SNPs in or within 1000 base pairs (bp) upstream of the known genes located in the 3q24-25 region (P2Y12 locus) were identified. By means of DNA sequencing using BigDye v. 3.1 (Applied Biosystems, CA, USA) in 20 individuals, selected SNPs were probed for linkage disequilibrium with the known P2Y<sub>12</sub> H2 haplotype SNPs using one of the P2Y<sub>12</sub> H2 SNPs, rs2046934, as a marker of the P2Y12 H2 haplotype <xref ref-type="bibr" rid="pone.0001462-Fontana1">&#x0005b;11&#x0005d;</xref>. Single nucleotide polymorphisms (SNPs) that displayed high degrees of LD with the P2Y<sub>12</sub> H1/H2 haplotype SNPs were selected for genotyping in a randomly selected sub-population of the DM case-control population (n&#x0200a;&#x0003d;&#x0200a;295) using TaqMan or Sequenom and a haplotype map was constructed using the Haploview software <xref ref-type="bibr" rid="pone.0001462-Barrett1">&#x0005b;24&#x0005d;</xref>.</p><p>Genotyping of the AMI (n&#x0200a;&#x0003d;&#x0200a;3732) and DM (n&#x0200a;&#x0003d;&#x0200a;614) case control populations and the cardiovascular group population (n&#x0200a;&#x0003d;&#x0200a;6055) was performed using Sequenom (Sequenom Inc., CA, USA) or TaqMan ABI 7900 according to the manufacturers' instructions. Two different persons who were unaware of the phenotypic status of the study participants read all genotypes. For genotyping primers and probes, see <xref ref-type="table" rid="pone-0001462-t002">table 2</xref>.</p><table-wrap id="pone-0001462-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0001462.t002</object-id><label>Table 2</label><caption><title>Primers and probes used for genotyping of high linkage disequilibrium polymorphisms in P2Y<sub>12</sub> and one in P2Y<sub>13</sub>.</title></caption><graphic id="pone-0001462-t002-2" xlink:href="pone.0001462.t002"/><table frame="hsides" rules="groups" alternate-form-of="pone-0001462-t002-2"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">SNP_ID</td><td align="left" rowspan="1" colspan="1">SNP location</td><td align="left" rowspan="1" colspan="1">Forward</td><td align="left" rowspan="1" colspan="1">Reverse</td><td align="left" rowspan="1" colspan="1">Mass Extension/Probes</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">rs1466684</td><td align="left" rowspan="1" colspan="1">P2Y<sub>13</sub> Met-158-Thr</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">&#x0002a;5&#x02032;-ACGTTGGATGGTGTTGCTTCCTTGTTGCTC-3&#x02032;</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">&#x0002a;5&#x02032;-ACGTTGGATGCGGTCTCAATCTTCATCTGG-3&#x02032;</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">&#x0002a;5&#x02032;-CATCTCCCTGCCAAATA-3&#x02032;</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">rs1466684</td><td align="left" rowspan="1" colspan="1">P2Y<sub>13</sub> Met-158-Thr</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene"><sup>#</sup>5&#x02032;-CGGTCTCAATCTTCATCTGGTTCTT-3&#x02032;</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene"><sup>#</sup>5&#x02032;-CGATGGTGTTGCTTCCTTGTTG-3&#x02032;</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene"><sup>#</sup>5&#x02032;-CTCAAGATCATATTTGG-3&#x02032;</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><named-content content-type="gene"><sup>#</sup>5&#x02032;-CTCAAGATCGTATTTGG-3&#x02032;</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">rs11922647</td><td align="left" rowspan="1" colspan="1">P2Y<sub>12</sub> intron 1</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">&#x0002a;5&#x02032;-ACGTTGGATGTTAAGGCATCCTTGTATCAC-3&#x02032;</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">&#x0002a;5&#x02032;-ACGTTGGATGCCCCTAACATATTTTTTGCCC-3&#x02032;</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">&#x0002a;5&#x02032;-CCTTCTGGTTTCAAAGTTAAA-3&#x02032;</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">rs3821667</td><td align="left" rowspan="1" colspan="1">P2Y<sub>12</sub> untranslated</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">&#x0002a;5&#x02032;-ACGTTGGATGTGTTGATTCTGGAGGGTTTG-3&#x02032;</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">&#x0002a;5&#x02032;-ACGTTGGATGAGGAAAATACCAGATGCCAC</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">&#x0002a;5&#x02032;-AGATGCCACTCTGCAGG-3&#x02032;</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">rs2046934</td><td align="left" rowspan="1" colspan="1">P2Y<sub>12</sub> intron 2</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">#5&#x02032;-GCTATATGGCATCTACATCTTGGGAAT-3&#x02032;</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">#5&#x02032;-TGATTATTAAGAATATTTTATATAGAATCAATTTCACTTATCTCTGGTG-3&#x02032;</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">#5&#x02032;-TTGAAATGACATTTGTAATCT-3&#x02032;</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">#5&#x02032;-AAATGACGTTTGTAATCT-3&#x02032;</named-content></td></tr></tbody></table><table-wrap-foot><fn id="nt102"><p>Some SNPs were genotyped with both Sequenom and TaqMan in different populations. &#x0002a;Sequenom, # TaqMan.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2f"><title>Statistical analysis</title><p>In the AMI case control population, conditional logistic regression was used to calculate odds ratios and p values. The Cardiovascular group population was subjected to ANOVA and t-tests for continuous normally distributed variables, in case of non-normality Kruskal-Wallis test or Mann-Whitney test was used. Chi-2 test was used to test for significant differences in dichotomous variables. In the DM case control population, variables were log transformed for normal distribution. P-values were calculated using the GLM-ANCOVA using sex and age as covariates. Adjustment for multiple testing was not done. Statistical analyses were performed with SPSS.</p></sec><sec id="s2g"><title>Power calculations</title><sec id="s2g1"><title>For myocardial infarction</title><p>Accepting a significance level of 0.05, 1244 AMI cases and 2488 controls have a power of 95&#x00025; to detect a genotype relative risk of 1.20 for the P2Y<sub>13</sub> Met-158-Thr polymorphism. Thus, it is unlikely that our result is a false negative finding.</p></sec><sec id="s2g2"><title>For diabetes</title><p>Accepting a significance level of 0.05, 307 diabetes cases and 307 controls have a power of 35&#x00025; to detect a genotype relative risk of 1.20 for the P2Y<sub>13</sub> Met-158-Thr polymorphism. Accepting a significance level of 0.05, 532 diabetes cases and 5522 controls in the cardiovascular group population have a power of 79&#x00025; to detect a genotype relative risk of 1.20 for the P2Y<sub>13</sub> Met-158-Thr polymorphism. By analyzing both these two diabetes materials, it is unlikely that our result that the P2Y<sub>13</sub> Met-158-Thr polymorphism is not associated with diabetes is a false negative finding. Powercalculations were performed using the program CaTS <xref ref-type="bibr" rid="pone.0001462-Skol1">&#x0005b;25&#x0005d;</xref>.</p></sec></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>Extent of P2Y<sub>12</sub> H2 haplotype linkage disequilibrium</title><p>The pilot linkage disequilibrium analysis of SNPs in the P2Y<sub>12</sub> locus revealed three SNPs (rs1466684, rs38211667, rs11922647) that showed signs of LD with the known P2Y<sub>12</sub> H2 SNPs. Genotyping in a larger population (n&#x0200a;&#x0003d;&#x0200a;295) confirmed complete LD of the three SNPs with the P2Y<sub>12</sub> H2 haplotype SNPs (D&#x02032;&#x0200a;&#x0003d;&#x0200a;1.0, r<sup>2</sup>&#x0200a;&#x0003d;&#x0200a;0.936&#x02013;1.0, <xref ref-type="fig" rid="pone-0001462-g001">figure 1</xref>) <xref ref-type="bibr" rid="pone.0001462-Fontana1">&#x0005b;11&#x0005d;</xref>. Two of the three SNPs were located in or in close proximity to the P2Y<sub>12</sub> gene: rs38211667 in the non-coding region of P2Y<sub>12</sub> exon 2 and rs11922647 within 1000 bp of transcription start of transcript variant 2 of the P2Y<sub>12</sub> gene. The third SNP (rs1466684) was found to be a non-synonymous SNP of the P2Y<sub>13</sub> gene, causing a Met-Thr amino acid substitution at position 158 of the P2Y<sub>13</sub> receptor. The complete LD of the P2Y<sub>12</sub> H2 haplotype with the P2Y<sub>13</sub> Thr-158 variant thus defines a novel P2Y<sub>12</sub> H2/P2Y<sub>13</sub> Thr-158 haplotype. The P2Y<sub>13</sub> Met-158-Thr polymorphism was selected as reference SNP for the P2Y<sub>12</sub> H2/P2Y<sub>13</sub> Thr-158 haplotype in subsequent genotyping.</p><fig id="pone-0001462-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0001462.g001</object-id><label>Figure 1</label><caption><title>Linkage disequilibrium map of the P2Y12 H2/P2Y13 Thr-158 haplotype.</title><p>All examined SNPs displayed a very high degree of linkage disequilibrium (D&#x02032;&#x0200a;&#x0003d;&#x0200a;1.0; r<sup>2</sup>&#x0200a;&#x0003d;&#x0200a;0.936&#x02013;1.0 (see figure for each individual r<sup>2</sup> value).</p></caption><graphic xlink:href="pone.0001462.g001"/></fig></sec><sec id="s3b"><title>Genotyping of the P2Y<sub>12</sub> H2/P2Y<sub>13</sub> Thr-158 haplotype in the AMI and DM case control populations</title><p>In the AMI case control population, containing 3273 individuals, 92.8&#x00025; of those eligible for the case&#x02013;control study were genotyped successfully (<xref ref-type="table" rid="pone-0001462-t003">table 3</xref>), representing 1134 pairs in total (n&#x0200a;&#x0003d;&#x0200a;1134 cases and one to two control subjects matching every case (n&#x0200a;&#x0003d;&#x0200a;2139). Genotype frequencies were in accordance with Hardy&#x02013;Weinberg Equilibrium.</p><table-wrap id="pone-0001462-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0001462.t003</object-id><label>Table 3</label><caption><title>Genotyping of Met-158-Thr in AMI cases and corresponding controls.</title></caption><graphic id="pone-0001462-t003-3" xlink:href="pone.0001462.t003"/><table frame="hsides" rules="groups" alternate-form-of="pone-0001462-t003-3"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Met-158-Met</td><td align="left" rowspan="1" colspan="1">Met-158-Thr</td><td align="left" rowspan="1" colspan="1">Thr-158-Thr</td><td align="left" rowspan="1" colspan="1">Met-158-Thr&#x0002b;Thr-158-Thr</td><td align="left" rowspan="1" colspan="1">Total</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Control count n (&#x00025;)</bold></td><td align="left" rowspan="1" colspan="1">1437 (67.2)</td><td align="left" rowspan="1" colspan="1">638 (29.8)</td><td align="left" rowspan="1" colspan="1">64 (3)</td><td align="left" rowspan="1" colspan="1">702 (33)</td><td align="left" rowspan="1" colspan="1">2139 (100)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>AMI count n (&#x00025;)</bold></td><td align="left" rowspan="1" colspan="1">772 (68.1)</td><td align="left" rowspan="1" colspan="1">332 (29.3)</td><td align="left" rowspan="1" colspan="1">30 (2.6)</td><td align="left" rowspan="1" colspan="1">362 (32)</td><td align="left" rowspan="1" colspan="1">1134 (100)</td></tr><tr><td colspan="6" align="left" rowspan="1"><italic>Early onset AMI</italic></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>EO Control count n (&#x00025;)</bold></td><td align="left" rowspan="1" colspan="1">715 (66)</td><td align="left" rowspan="1" colspan="1">323 (29.8)</td><td align="left" rowspan="1" colspan="1">31 (2.9)</td><td align="left" rowspan="1" colspan="1">354 (33.1)</td><td align="left" rowspan="1" colspan="1">1069 (100)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>EO AMI count n (&#x00025;)</bold></td><td align="left" rowspan="1" colspan="1">368 (64.7)</td><td align="left" rowspan="1" colspan="1">176 (35.3)</td><td align="left" rowspan="1" colspan="1">16 (3.2)</td><td align="left" rowspan="1" colspan="1">192 (34.3)</td><td align="left" rowspan="1" colspan="1">560 (100)</td></tr><tr><td colspan="6" align="left" rowspan="1"><italic>Late onset of AMI</italic></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>LO Control count n (&#x00025;)</bold></td><td align="left" rowspan="1" colspan="1">722 (67.5)</td><td align="left" rowspan="1" colspan="1">315 (29.4)</td><td align="left" rowspan="1" colspan="1">33 (3.1)</td><td align="left" rowspan="1" colspan="1">348 (33)</td><td align="left" rowspan="1" colspan="1">1070 (100)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>LO AMI count n (&#x00025;)</bold></td><td align="left" rowspan="1" colspan="1">404 (70.4)</td><td align="left" rowspan="1" colspan="1">156 (27.2)</td><td align="left" rowspan="1" colspan="1">14 (2.4)</td><td align="left" rowspan="1" colspan="1">170 (30)</td><td align="left" rowspan="1" colspan="1">574 (100)</td></tr><tr><td colspan="6" align="left" rowspan="1"><italic>Family history of AMI</italic></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>FH Control count n(&#x00025;)</bold></td><td align="left" rowspan="1" colspan="1">723 (68.3)</td><td align="left" rowspan="1" colspan="1">301 (28.4)</td><td align="left" rowspan="1" colspan="1">35 (3.3)</td><td align="left" rowspan="1" colspan="1">336 (32)</td><td align="left" rowspan="1" colspan="1">1059 (100)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>FH AMI count n (&#x00025;)</bold></td><td align="left" rowspan="1" colspan="1">387 (69)</td><td align="left" rowspan="1" colspan="1">157 (28)</td><td align="left" rowspan="1" colspan="1">17 (3)</td><td align="left" rowspan="1" colspan="1">174 (31)</td><td align="left" rowspan="1" colspan="1">561 (100)</td></tr><tr><td colspan="6" align="left" rowspan="1"><italic>No family history of AMI</italic></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>NFH Control count n(&#x00025;)</bold></td><td align="left" rowspan="1" colspan="1">714 (66.1)</td><td align="left" rowspan="1" colspan="1">337 (31.2)</td><td align="left" rowspan="1" colspan="1">29 (2.7)</td><td align="left" rowspan="1" colspan="1">366 (34)</td><td align="left" rowspan="1" colspan="1">1080 (100)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>NFH AMI count n (&#x00025;)</bold></td><td align="left" rowspan="1" colspan="1">385 (67.2)</td><td align="left" rowspan="1" colspan="1">175 (30.5)</td><td align="left" rowspan="1" colspan="1">13 (2.3)</td><td align="left" rowspan="1" colspan="1">188 (33)</td><td align="left" rowspan="1" colspan="1">573 (100)</td></tr><tr><td colspan="6" align="left" rowspan="1"><italic>Early onset and family history of AMI</italic></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>EO&#x0002b;FH Control count n (&#x00025;)</bold></td><td align="left" rowspan="1" colspan="1">373 (67.6)</td><td align="left" rowspan="1" colspan="1">159 (28.8)</td><td align="left" rowspan="1" colspan="1">20 (3.6)</td><td align="left" rowspan="1" colspan="1">179 (32)</td><td align="left" rowspan="1" colspan="1">552 (100)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>EO&#x0002b;FH AMI count n (&#x00025;)</bold></td><td align="left" rowspan="1" colspan="1">197 (67.9)</td><td align="left" rowspan="1" colspan="1">87 (30)</td><td align="left" rowspan="1" colspan="1">6 (2.1)</td><td align="left" rowspan="1" colspan="1">93 (32)</td><td align="left" rowspan="1" colspan="1">290 (100)</td></tr></tbody></table><table-wrap-foot><fn id="nt103"><p>The AMI case group (<italic>n</italic>&#x0200a;&#x0003d;&#x0200a;1244) contains the early onset (EO), late onset (LO), family history (FH) and no family history (NFH) as well as early onset with family history (EO&#x0002b;FH) subgroups. &#x0002a;Both heterozygous and homozygous P2RY<sub>13</sub> Thr-158 carriers.</p></fn></table-wrap-foot></table-wrap><p>No association of the P2Y<sub>13</sub> Met-158-Thr polymorphism (Thr-158-Met and Thr-158-Thr vs. Met-158-Met) was found with AMI (OR&#x0200a;&#x0003d;&#x0200a;0.96, 95&#x00025; C.I. 0.82&#x02013;1.12, P&#x0200a;&#x0003d;&#x0200a;0.63). Also, no differences were seen in the AMI case subpopulations (EO OR&#x0200a;&#x0003d;&#x0200a;1.06, 95&#x00025; C.I. 0.85&#x02013;1.31, P&#x0200a;&#x0003d;&#x0200a;0.62; FH OR&#x0200a;&#x0003d;&#x0200a;0.98, 95&#x00025; C.I. 0.78&#x02013;1.22, P&#x0200a;&#x0003d;&#x0200a;0.83; EO&#x0002b;FH OR&#x0200a;&#x0003d;&#x0200a;1.0, 95&#x00025; C.I. 0.74&#x02013;1.36, P&#x0200a;&#x0003d;&#x0200a;1.0).</p><p>In the diabetes mellitus (DM) case control study 576 individuals (93.8&#x00025;) were genotyped successfully. No associations of the P2Y13 polymorphism (Thr-158-Met and Thr-158-Thr vs. Met-158-Met) were found with diabetes mellitus or any examined DM risk factor (<xref ref-type="table" rid="pone-0001462-t004">table 4</xref>).</p><table-wrap id="pone-0001462-t004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0001462.t004</object-id><label>Table 4</label><caption><title>Genotyping of the P2Y<sub>12</sub> H2/P2Y<sub>13</sub> Thr-158 haplotype in a diabetes mellitus (DM) case control population (307 DM cases, 307 controls).</title></caption><graphic id="pone-0001462-t004-4" xlink:href="pone.0001462.t004"/><table frame="hsides" rules="groups" alternate-form-of="pone-0001462-t004-4"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Controls (n&#x0200a;&#x0003d;&#x0200a;289)&#x000a7;</td><td align="left" rowspan="1" colspan="1">Met-158 &#x0005b;n&#x0005d;#</td><td align="left" rowspan="1" colspan="1">Thr-158&#x0002a; &#x0005b;n&#x0005d;#</td><td align="left" rowspan="1" colspan="1">p-value</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="left" rowspan="1" colspan="1">26.4(24.1&#x02013;29.2) &#x0005b;213&#x0005d;</td><td align="left" rowspan="1" colspan="1">26.6(24.2&#x02013;29.3) &#x0005b;70&#x0005d;</td><td align="left" rowspan="1" colspan="1"><bold>0.49</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">WH</td><td align="left" rowspan="1" colspan="1">0.88(0.82&#x02013;0.95) &#x0005b;211&#x0005d;</td><td align="left" rowspan="1" colspan="1">0.88(0.82&#x02013;0.96)&#x0005b;70&#x0005d;</td><td align="left" rowspan="1" colspan="1"><bold>0.64</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">fP-Glu (mmol/L)</td><td align="left" rowspan="1" colspan="1">5.42(5.09&#x02013;5.80) &#x0005b;214&#x0005d;</td><td align="left" rowspan="1" colspan="1">5.50(5.06&#x02013;5.93) &#x0005b;73&#x0005d;</td><td align="left" rowspan="1" colspan="1"><bold>0.56</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">P-Glu &#x0005b;120 min&#x0005d; (mmol/L)</td><td align="left" rowspan="1" colspan="1">5.65(4.97&#x02013;6.70) &#x0005b;191&#x0005d;</td><td align="left" rowspan="1" colspan="1">5.82(5.02&#x02013;6.75) &#x0005b;64&#x0005d;</td><td align="left" rowspan="1" colspan="1"><bold>0.90</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">fP-INS (mU/L)</td><td align="left" rowspan="1" colspan="1">7.66(4.95&#x02013;10.22) &#x0005b;210&#x0005d;</td><td align="left" rowspan="1" colspan="1">6.55(4.66&#x02013;9.47) &#x0005b;68&#x0005d;</td><td align="left" rowspan="1" colspan="1"><bold>0.10</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Triglycerids (mmol/L)</td><td align="left" rowspan="1" colspan="1">1.17(0.92&#x02013;1.67) &#x0005b;198&#x0005d;</td><td align="left" rowspan="1" colspan="1">1.32(0.81&#x02013;1.69) &#x0005b;65&#x0005d;</td><td align="left" rowspan="1" colspan="1"><bold>0.86</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">HDL-cholesterol (mmol/L)</td><td align="left" rowspan="1" colspan="1">1.36(1.16&#x02013;1.66) &#x0005b;199&#x0005d;</td><td align="left" rowspan="1" colspan="1">1.37(1.18&#x02013;1.73) &#x0005b;64&#x0005d;</td><td align="left" rowspan="1" colspan="1"><bold>0.91</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">HOMA</td><td align="left" rowspan="1" colspan="1">1.76(1.18&#x02013;2.53) &#x0005b;207&#x0005d;</td><td align="left" rowspan="1" colspan="1">1.68(1.05&#x02013;2.49) &#x0005b;68&#x0005d;</td><td align="left" rowspan="1" colspan="1"><bold>0.13</bold></td></tr></tbody></table><table frame="hsides" rules="groups" alternate-form-of="pone-0001462-t004-4"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Diabetes mellitus (n&#x0200a;&#x0003d;&#x0200a;287)&#x000a7;</td><td align="left" rowspan="1" colspan="1">Met-158 &#x0005b;n&#x0005d;#</td><td align="left" rowspan="1" colspan="1">Thr-158&#x0002a; &#x0005b;n&#x0005d;#</td><td align="left" rowspan="1" colspan="1">p-value</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age at onset (years)</td><td align="left" rowspan="1" colspan="1">53(46&#x02013;59) &#x0005b;201&#x0005d;</td><td align="left" rowspan="1" colspan="1">53(48&#x02013;60) &#x0005b;74&#x0005d;</td><td align="left" rowspan="1" colspan="1"><bold>0.67</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="left" rowspan="1" colspan="1">28.7(25.9&#x02013;31.7) &#x0005b;206&#x0005d;</td><td align="left" rowspan="1" colspan="1">28.2(25.7&#x02013;31.2) &#x0005b;78&#x0005d;</td><td align="left" rowspan="1" colspan="1"><bold>0.53</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">WH</td><td align="left" rowspan="1" colspan="1">0.93(0.87&#x02013;0.99) &#x0005b;202&#x0005d;</td><td align="left" rowspan="1" colspan="1">0.94(0.90&#x02013;1.00) &#x0005b;77&#x0005d;</td><td align="left" rowspan="1" colspan="1"><bold>0.76</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">fP-Glu (mmol/L)</td><td align="left" rowspan="1" colspan="1">9.49(7.90&#x02013;11.75) &#x0005b;207&#x0005d;</td><td align="left" rowspan="1" colspan="1">8.87(7.12&#x02013;11.35) &#x0005b;78&#x0005d;</td><td align="left" rowspan="1" colspan="1"><bold>0.28</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">P-Glu &#x0005b;120 min&#x0005d; (mmol/L)</td><td align="left" rowspan="1" colspan="1">15.43(11.67&#x02013;20.18) &#x0005b;108&#x0005d;</td><td align="left" rowspan="1" colspan="1">14.24(12.37&#x02013;16.84) &#x0005b;37&#x0005d;</td><td align="left" rowspan="1" colspan="1"><bold>0.16</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">fP-INS (mU/L)</td><td align="left" rowspan="1" colspan="1">11.95(6.99&#x02013;21.15) &#x0005b;198&#x0005d;</td><td align="left" rowspan="1" colspan="1">11.54(7.87&#x02013;19.09) &#x0005b;77&#x0005d;</td><td align="left" rowspan="1" colspan="1"><bold>0.60</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Triglycerids (mmol/L)</td><td align="left" rowspan="1" colspan="1">1.57(1.15&#x02013;2.21) &#x0005b;197&#x0005d;</td><td align="left" rowspan="1" colspan="1">1.66(1.21&#x02013;2.39) &#x0005b;75&#x0005d;</td><td align="left" rowspan="1" colspan="1"><bold>0.17</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">HDL-cholesterol (mmol/L)</td><td align="left" rowspan="1" colspan="1">1.19(1.02&#x02013;1.45) &#x0005b;191&#x0005d;</td><td align="left" rowspan="1" colspan="1">1.15(1.01&#x02013;1.36) &#x0005b;71&#x0005d;</td><td align="left" rowspan="1" colspan="1"><bold>0.31</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">HOMA</td><td align="left" rowspan="1" colspan="1">4.98(3.00&#x02013;9.20) &#x0005b;197&#x0005d;</td><td align="left" rowspan="1" colspan="1">4.70(3.00&#x02013;9.88) &#x0005b;77&#x0005d;</td><td align="left" rowspan="1" colspan="1"><bold>0.30</bold></td></tr></tbody></table><table-wrap-foot><fn id="nt104"><p>Variables were log-transformed for normal distribution. P-values were calculated using the GLM-ANCOVA using sex and age as covariates. No associations were found with neither DM nor any known DM risk factor. &#x0002a;Both heterozygous and homozygous P2Y<sub>12</sub> H2/P2Y<sub>13</sub> Thr-158 carriers. &#x000a7;Genotyping failed in 20 cases and 18 controls. #median with interquartile range (25th&#x02013;75th percentile), &#x0005b;number of observations&#x0005d;.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3c"><title>Genotyping of P2Y<sub>13</sub> Met-158-Thr in the cardiovascular group population</title><p>5846 individuals (96.5&#x00025;) of 6055 in the cardiovascular group (CVG) were genotyped successfully. No association was found for the P2Y<sub>13</sub> Met-158-Thr polymorphism (Thr-158-Met and Thr-158-Thr vs. Met-158-Met) regarding any of the examined cardiovascular risk factors, including systolic blood pressure, diastolic blood pressure, BMI, waist circ., diabetes, total cholesterol, triglycerides, HDL, LDL, CRP, smoking or alcohol intake (<xref ref-type="table" rid="pone-0001462-t005">table 5</xref>). Furthermore, no stronger association with the above mentioned risk factors was seen in the homozygous P2Y<sub>13</sub> Thr-158 group compared to the heterozygous Met-158-Thr carriers (data not shown).</p><table-wrap id="pone-0001462-t005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0001462.t005</object-id><label>Table 5</label><caption><title>Association of known cardiovascular risk factors with the P2Y<sub>12</sub> H2/P2Y<sub>13</sub> Thr-158 genotype in the cardiovascular group (CVG).</title></caption><graphic id="pone-0001462-t005-5" xlink:href="pone.0001462.t005"/><table frame="hsides" rules="groups" alternate-form-of="pone-0001462-t005-5"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Cardiovascular risk factors</td><td align="left" rowspan="1" colspan="1">Met-158-Thr genotype&#x000a4;</td><td align="left" rowspan="1" colspan="1">Mean&#x000b1;st dev</td><td align="left" rowspan="1" colspan="1">P value (two-tailed)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Systolic blood pressure (mm Hg)</td><td align="left" rowspan="1" colspan="1">Met</td><td align="left" rowspan="1" colspan="1">141.6&#x000b1;19.1</td><td align="left" rowspan="1" colspan="1">0.60</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Thr&#x000a4;</td><td align="left" rowspan="1" colspan="1">141.3&#x000b1;19.1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Diastolic blood pressure (mm Hg)</td><td align="left" rowspan="1" colspan="1">Met</td><td align="left" rowspan="1" colspan="1">87.3&#x000b1;9.5</td><td align="left" rowspan="1" colspan="1">0.15</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Thr&#x000a4;</td><td align="left" rowspan="1" colspan="1">86.9&#x000b1;9.4</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Body-Mass Index (weight/kg&#x000d7;kg)</td><td align="left" rowspan="1" colspan="1">Met</td><td align="left" rowspan="1" colspan="1">26.0&#x000b1;4.0</td><td align="left" rowspan="1" colspan="1">0.16</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Thr&#x000a4;</td><td align="left" rowspan="1" colspan="1">25.8&#x000b1;4.0</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Waist (cm)</td><td align="left" rowspan="1" colspan="1">Met</td><td align="left" rowspan="1" colspan="1">84.7&#x000b1;12.9</td><td align="left" rowspan="1" colspan="1">0.09</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Thr&#x000a4;</td><td align="left" rowspan="1" colspan="1">84.1&#x000b1;13.0</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes mellitus (&#x00025;)&#x0002a;</td><td align="left" rowspan="1" colspan="1">Met</td><td align="left" rowspan="1" colspan="1">8.8</td><td align="left" rowspan="1" colspan="1">0.94</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Thr&#x000a4;</td><td align="left" rowspan="1" colspan="1">8.9</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Cholesterol (mmol/l)&#x0002a;</td><td align="left" rowspan="1" colspan="1">Met</td><td align="left" rowspan="1" colspan="1">6.2&#x000b1;1.0</td><td align="left" rowspan="1" colspan="1">0.93</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Thr&#x000a4;</td><td align="left" rowspan="1" colspan="1">6.2&#x000b1;1.1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Triglycerides (mmol/l)&#x0002a;</td><td align="left" rowspan="1" colspan="1">Met</td><td align="left" rowspan="1" colspan="1">1.4&#x000b1;0.9</td><td align="left" rowspan="1" colspan="1">0.38</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Thr&#x000a4;</td><td align="left" rowspan="1" colspan="1">1.4&#x000b1;0.8</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">HDL (mmol/l)&#x0002a;</td><td align="left" rowspan="1" colspan="1">Met</td><td align="left" rowspan="1" colspan="1">1.4&#x000b1;0.4</td><td align="left" rowspan="1" colspan="1">0.78</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Thr&#x000a4;</td><td align="left" rowspan="1" colspan="1">1.4&#x000b1;0.4</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">LDL (mmol/l)&#x0002a;</td><td align="left" rowspan="1" colspan="1">Met</td><td align="left" rowspan="1" colspan="1">4.2&#x000b1;1.0</td><td align="left" rowspan="1" colspan="1">0.96</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Thr&#x000a4;</td><td align="left" rowspan="1" colspan="1">4.2&#x000b1;1.0</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">LDL/HDL ratio&#x0002a;</td><td align="left" rowspan="1" colspan="1">Met</td><td align="left" rowspan="1" colspan="1">3.2&#x000b1;1.1</td><td align="left" rowspan="1" colspan="1">0.91</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Thr&#x000a4;</td><td align="left" rowspan="1" colspan="1">3.2&#x000b1;1.2</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CRP (mg/L)&#x0002a;#</td><td align="left" rowspan="1" colspan="1">Met</td><td align="left" rowspan="1" colspan="1">&#x000a7;1.4 (0.7&#x02013;2.8)</td><td align="left" rowspan="1" colspan="1">0.83</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Thr&#x000a4;</td><td align="left" rowspan="1" colspan="1">&#x000a7;1.4 (0.7&#x02013;2.9)</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="nt105"><p>Gaussian distribution was observed for all above risk factors except CRP that showed a natural logarithmic distribution. <italic>n</italic>&#x0200a;&#x0003d;&#x0200a;6055. &#x0002a; <italic>n</italic>&#x0200a;&#x0003d;&#x0200a;5540. &#x000a7;&#x0200a;&#x0003d;&#x0200a;median, interquartile range. &#x000a4;Thr&#x0200a;&#x0003d;&#x0200a;Both heterozygous and homozygous P2RY<sub>13</sub> Thr-158 carriers.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s4"><title>Discussion</title><p>In this study we show that the P2Y<sub>12</sub> H2 haplotype <xref ref-type="bibr" rid="pone.0001462-Fontana1">&#x0005b;11&#x0005d;</xref> is in complete linkage disequilibrium with the non-synonymous Met-158-Thr polymorphism in the P2Y<sub>13</sub> gene, defining a P2Y<sub>12</sub> H2/P2Y<sub>13</sub> Thr-158 haplotype. Based on the observed LD between the studied P2Y<sub>12</sub> and P2Y<sub>13</sub> polymorphisms, we assume that all disease and risk factor associations made with the P2Y<sub>13</sub> Met-158-Thr polymorphisms are also valid for the P2Y<sub>12</sub> H1/H2 haplotypes. We hypothesized that this finding could provide a potential mechanistic explanation to the previously observed clinical associations of the P2Y<sub>12</sub> H2 haplotype with CAD, PAD or platelet function <xref ref-type="bibr" rid="pone.0001462-Fontana1">&#x0005b;11&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0001462-Fontana2">&#x0005b;12&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0001462-Cavallari1">&#x0005b;14&#x0005d;</xref>, since the receptors share the same ligand. However, no associations of the P2Y<sub>13</sub> Met-158-Thr polymorphism with AMI or DM were found in our large material. Indeed, no associations with any of the investigated cardiovascular or diabetes mellitus risk factors were observed. This was unexpected, since strong associations have been reported between CAD, PAD, AMI and diabetes <xref ref-type="bibr" rid="pone.0001462-Lee1">&#x0005b;18&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0001462-McCullough1">&#x0005b;20&#x0005d;</xref>. All studies involving the P2Y12 H2 haplotype are listed in <xref ref-type="table" rid="pone-0001462-t006">table 6</xref>.</p><table-wrap id="pone-0001462-t006" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0001462.t006</object-id><label>Table 6</label><caption><title>Published studies on the P2Y12 H2 haplotype and platelet ADP response and cardiovascular disease.</title></caption><graphic id="pone-0001462-t006-6" xlink:href="pone.0001462.t006"/><table frame="hsides" rules="groups" alternate-form-of="pone-0001462-t006-6"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Study author</td><td align="left" rowspan="1" colspan="1">Study population (n)</td><td align="left" rowspan="1" colspan="1">Reported outcome</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Fontana <xref ref-type="bibr" rid="pone.0001462-Fontana1">&#x0005b;11&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">98</td><td align="left" rowspan="1" colspan="1">P2Y12 H2 haplotype is associated with increased ADP-induced platelet aggregation</td></tr><tr><td align="left" rowspan="1" colspan="1">Fontana <xref ref-type="bibr" rid="pone.0001462-Fontana1">&#x0005b;11&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">514</td><td align="left" rowspan="1" colspan="1">P2Y12 H2 haplotype is associated with peripheral arterial disease</td></tr><tr><td align="left" rowspan="1" colspan="1">Cavallari <xref ref-type="bibr" rid="pone.0001462-Cavallari1">&#x0005b;14&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">1378</td><td align="left" rowspan="1" colspan="1">The P2Y12 H2 haplotype is associated with coronary artery disease</td></tr><tr><td align="left" rowspan="1" colspan="1">Angiolillo <xref ref-type="bibr" rid="pone.0001462-Angiolillo1">&#x0005b;30&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">119</td><td align="left" rowspan="1" colspan="1">The P2Y12 H2 haplotype does not influence platelet response to clopidogrel</td></tr><tr><td align="left" rowspan="1" colspan="1">Hetherington <xref ref-type="bibr" rid="pone.0001462-Hetherington1">&#x0005b;31&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">200</td><td align="left" rowspan="1" colspan="1">No association of P2Y12 H2 haplotype with ADP-induced platelet aggregation</td></tr><tr><td align="left" rowspan="1" colspan="1">von Beckerath <xref ref-type="bibr" rid="pone.0001462-vonBeckerath1">&#x0005b;17&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">416</td><td align="left" rowspan="1" colspan="1">P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose</td></tr><tr><td align="left" rowspan="1" colspan="1">Schettert <xref ref-type="bibr" rid="pone.0001462-Schettert1">&#x0005b;16&#x0005d;</xref></td><td align="left" rowspan="1" colspan="1">540</td><td align="left" rowspan="1" colspan="1">No asociation of P2Y12 H2 haplotype and an increased risk of cardiovascular events in a population with CAD</td></tr><tr><td align="left" rowspan="1" colspan="1">Amisten <italic>et al</italic></td><td align="left" rowspan="1" colspan="1">10401</td><td align="left" rowspan="1" colspan="1">The P2Y12 H2/P2Y13 Thr-158 haplotype is not associated with AMI, cardiovascular risk factors or diabetes</td></tr></tbody></table></table-wrap><p>The concentration of extracellular nucleotides in the blood is tightly regulated by ectonucleotidases on leukocyte and endothelial cells to prevent excessive ADP accumulation and subsequent platelet activation <xref ref-type="bibr" rid="pone.0001462-Coade1">&#x0005b;26&#x0005d;</xref>. Red blood cells contain millimolar amounts of ATP and are therefore a major source of nucleotides in the blood <xref ref-type="bibr" rid="pone.0001462-Wang1">&#x0005b;6&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0001462-Bergfeld1">&#x0005b;27&#x0005d;</xref>. This ATP pool could potentially be an important contributor to the regulation of platelet activation. Recently, it was shown that extracellular ADP activates P2Y<sub>13</sub> expressed on red blood cells, resulting in a subsequent decreased release of nucleotides from the red blood cells in a classic negative feedback manner <xref ref-type="bibr" rid="pone.0001462-Wang1">&#x0005b;6&#x0005d;</xref>. It is possible that this negative feedback loop might be important in the regulation of nucleotide-induced platelet activation <italic>in vivo</italic>. Thus, a non-synonymous polymorphism leading to a structurally and functionally altered P2Y<sub>13</sub> could potentially alter the nucleotide concentrations in the blood stream, thereby affecting platelet activation <italic>in vivo</italic>. Indeed, <italic>in silico</italic> analysis using the polymorphism phenotyping prediction software PolyPhen <xref ref-type="bibr" rid="pone.0001462-Ramensky1">&#x0005b;28&#x0005d;</xref> indicated that the P2Y<sub>13</sub> Met-158-Thr amino acid substitution could possible affect the function of the P2Y<sub>13</sub> receptor.</p><p>In 2002 Fontana <italic>et al</italic> reported the P2Y<sub>12</sub> H2 haplotype to be associated with a gain of function in terms of ADP induced platelet aggregation. The polymorphisms in the H2 haplotype are either located in intronic regions of the gene or were silent, i.e. causing no alterations of the P2Y<sub>12</sub> receptor protein. The possibility remained that the polymorphisms could potentially be coupled to mRNA processing or translation events, thereby altering P2Y<sub>12</sub> receptor protein expression. However, no such data has been presented.</p><p>In a subsequent study, Fontana <italic>et al</italic> also reported an association between the P2Y<sub>12</sub> H2 haplotype and PAD <xref ref-type="bibr" rid="pone.0001462-Fontana2">&#x0005b;12&#x0005d;</xref>. PAD causes an increased atherosclerotic burden throughout the whole cardiovasculature and patients with PAD have a marked increase in coronary artery disease <xref ref-type="bibr" rid="pone.0001462-Leng1">&#x0005b;29&#x0005d;</xref>. The progression of chronic atherosclerotic lesions is mainly driven by an inflammatory reaction, with recruitment of inflammatory cells and subsequent reactive changes in the vessel wall <xref ref-type="bibr" rid="pone.0001462-Amisten1">&#x0005b;21&#x0005d;</xref>. In acute thrombotic complications of atherosclerosis, such as myocardial infarction, platelets constitute the major role. A gain of function polymorphism leading to increased platelet reactivity would likely be more prominent when studied in a setting were platelet activation is a main pathogenic factor, such as AMI. However, to our surprise, genotyping in several thousand individuals revealed no association with AMI.</p><p>The early onset or family history AMI case-control subpopulations are believed to contain a stronger genetic component of AMI. The lack of association also in these populations emphasizes further that the P2Y<sub>12</sub> H2/P2Y<sub>13</sub> Thr-158 haplotype is not associated with cardiovascular disease.</p><p>It has been proposed that the P2Y<sub>12</sub> H2 haplotype might be involved in the variation in response to clopidogrel treatment. However, subsequent studies have not been able to confirm that variations in response after a high loading dose of clopidogrel are associated with the haplotype. The failure to confirm this hypothesis agrees well with our study and supports the lack of association of the P2Y<sub>12</sub> H2/P2Y<sub>13</sub> Thr-158 haplotype with cardiovascular disease.</p><p>In conclusion, we found that the P2Y<sub>13</sub> Met-158-Thr polymorphism was in complete LD with the P2Y<sub>12</sub> H2 haplotype, defining a novel P2Y<sub>12</sub> H2/P2Y<sub>13</sub> Thr-158 haplotype. Genotyping of more than 10 000 individuals in three separate study populations revealed no associations with AMI, DM or related risk factors. Therefore, it seems very unlikely that the examined polymorphisms of the P2Y<sub>12</sub> and P2Y<sub>13</sub> genes contribute to the pathogenesis of cardiovascular disease or diabetes mellitus<bold>.</bold></p></sec></body><back><ref-list><title>References</title><ref id="pone.0001462-Hollopeter1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hollopeter</surname><given-names>G</given-names></name><name><surname>Jantzen</surname><given-names>HM</given-names></name><name><surname>Vincent</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>England</surname><given-names>L</given-names></name><etal/></person-group><year>2001</year><article-title>Identification of the platelet ADP receptor targeted by antithrombotic drugs.</article-title><source>Nature</source><volume>409</volume><fpage>202</fpage><lpage>207</lpage><pub-id pub-id-type="pmid">11196645</pub-id></citation></ref><ref id="pone.0001462-Ayyanathan1"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ayyanathan</surname><given-names>K</given-names></name><name><surname>Webbs</surname><given-names>TE</given-names></name><name><surname>Sandhu</surname><given-names>AK</given-names></name><name><surname>Athwal</surname><given-names>RS</given-names></name><name><surname>Barnard</surname><given-names>EA</given-names></name><etal/></person-group><year>1996</year><article-title>Cloning and chromosomal localization of the human P2Y1 purinoceptor.</article-title><source>Biochem Biophys Res Commun</source><volume>218</volume><fpage>783</fpage><lpage>788</lpage><pub-id pub-id-type="pmid">8579591</pub-id></citation></ref><ref id="pone.0001462-Zhang1"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>FL</given-names></name><name><surname>Luo</surname><given-names>L</given-names></name><name><surname>Gustafson</surname><given-names>E</given-names></name><name><surname>Lachowicz</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>M</given-names></name><etal/></person-group><year>2001</year><article-title>ADP is the cognate ligand for the orphan G protein-coupled receptor SP1999.</article-title><source>J Biol Chem</source><volume>276</volume><fpage>8608</fpage><lpage>8615</lpage><pub-id pub-id-type="pmid">11104774</pub-id></citation></ref><ref id="pone.0001462-Communi1"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Communi</surname><given-names>D</given-names></name><name><surname>Gonzalez</surname><given-names>NS</given-names></name><name><surname>Detheux</surname><given-names>M</given-names></name><name><surname>Brezillon</surname><given-names>S</given-names></name><name><surname>Lannoy</surname><given-names>V</given-names></name><etal/></person-group><year>2001</year><article-title>Identification of a novel human ADP receptor coupled to G(i).</article-title><source>J Biol Chem</source><volume>276</volume><fpage>41479</fpage><lpage>41485</lpage><pub-id pub-id-type="pmid">11546776</pub-id></citation></ref><ref id="pone.0001462-Murugappa1"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murugappa</surname><given-names>S</given-names></name><name><surname>Kunapuli</surname><given-names>SP</given-names></name></person-group><year>2006</year><article-title>The role of ADP receptors in platelet function.</article-title><source>Front Biosci</source><volume>11</volume><fpage>1977</fpage><lpage>1986</lpage><pub-id pub-id-type="pmid">16368572</pub-id></citation></ref><ref id="pone.0001462-Wang1"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Olivecrona</surname><given-names>G</given-names></name><name><surname>Gotberg</surname><given-names>M</given-names></name><name><surname>Olsson</surname><given-names>ML</given-names></name><name><surname>Winzell</surname><given-names>MS</given-names></name><etal/></person-group><year>2005</year><article-title>ADP acting on P2Y13 receptors is a negative feedback pathway for ATP release from human red blood cells.</article-title><source>Circ Res</source><volume>96</volume><fpage>189</fpage><lpage>196</lpage><pub-id pub-id-type="pmid">15604418</pub-id></citation></ref><ref id="pone.0001462-Cattaneo1"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cattaneo</surname><given-names>M</given-names></name><name><surname>Zighetti</surname><given-names>ML</given-names></name><name><surname>Lombardi</surname><given-names>R</given-names></name><name><surname>Martinez</surname><given-names>C</given-names></name><name><surname>Lecchi</surname><given-names>A</given-names></name><etal/></person-group><year>2003</year><article-title>Molecular bases of defective signal transduction in the platelet P2Y12 receptor of a patient with congenital bleeding.</article-title><source>Proc Natl Acad Sci U S A</source><volume>100</volume><fpage>1978</fpage><lpage>1983</lpage><pub-id pub-id-type="pmid">12578987</pub-id></citation></ref><ref id="pone.0001462-Remijn1"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Remijn</surname><given-names>JA</given-names></name><name><surname>MJ</surname><given-names>IJ</given-names></name><name><surname>Strunk</surname><given-names>AL</given-names></name><name><surname>Abbes</surname><given-names>AP</given-names></name><name><surname>Engel</surname><given-names>H</given-names></name><etal/></person-group><year>2007</year><article-title>Novel molecular defect in the platelet ADP receptor P2Y12 of a patient with haemorrhagic diathesis.</article-title><source>Clin Chem Lab Med</source><volume>45</volume><fpage>187</fpage><lpage>189</lpage><pub-id pub-id-type="pmid">17311506</pub-id></citation></ref><ref id="pone.0001462-Bertrand1"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bertrand</surname><given-names>ME</given-names></name><name><surname>Simoons</surname><given-names>ML</given-names></name><name><surname>Fox</surname><given-names>KA</given-names></name><name><surname>Wallentin</surname><given-names>LC</given-names></name><name><surname>Hamm</surname><given-names>CW</given-names></name><etal/></person-group><year>2002</year><article-title>Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.</article-title><source>Eur Heart J</source><volume>23</volume><fpage>1809</fpage><lpage>1840</lpage><pub-id pub-id-type="pmid">12503543</pub-id></citation></ref><ref id="pone.0001462-Wiviott1"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wiviott</surname><given-names>SD</given-names></name><name><surname>Braunwald</surname><given-names>E</given-names></name><name><surname>McCabe</surname><given-names>CH</given-names></name><name><surname>Montalescot</surname><given-names>G</given-names></name><name><surname>Ruzyllo</surname><given-names>W</given-names></name><etal/></person-group><year>2007</year><article-title>Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes.</article-title><source>N Engl J Med</source></citation></ref><ref id="pone.0001462-Fontana1"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fontana</surname><given-names>P</given-names></name><name><surname>Dupont</surname><given-names>A</given-names></name><name><surname>Gandrille</surname><given-names>S</given-names></name><name><surname>Bachelot-Loza</surname><given-names>C</given-names></name><name><surname>Reny</surname><given-names>JL</given-names></name><etal/></person-group><year>2003</year><article-title>Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects.</article-title><source>Circulation</source><volume>108</volume><fpage>989</fpage><lpage>995</lpage><pub-id pub-id-type="pmid">12912815</pub-id></citation></ref><ref id="pone.0001462-Fontana2"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fontana</surname><given-names>P</given-names></name><name><surname>Gaussem</surname><given-names>P</given-names></name><name><surname>Aiach</surname><given-names>M</given-names></name><name><surname>Fiessinger</surname><given-names>JN</given-names></name><name><surname>Emmerich</surname><given-names>J</given-names></name><etal/></person-group><year>2003</year><article-title>P2Y12 H2 haplotype is associated with peripheral arterial disease: a case-control study.</article-title><source>Circulation</source><volume>108</volume><fpage>2971</fpage><lpage>2973</lpage><pub-id pub-id-type="pmid">14662702</pub-id></citation></ref><ref id="pone.0001462-Ziegler1"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ziegler</surname><given-names>S</given-names></name><name><surname>Schillinger</surname><given-names>M</given-names></name><name><surname>Funk</surname><given-names>M</given-names></name><name><surname>Felber</surname><given-names>K</given-names></name><name><surname>Exner</surname><given-names>M</given-names></name><etal/></person-group><year>2005</year><article-title>Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease.</article-title><source>Stroke</source><volume>36</volume><fpage>1394</fpage><lpage>1399</lpage><pub-id pub-id-type="pmid">15933261</pub-id></citation></ref><ref id="pone.0001462-Cavallari1"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cavallari</surname><given-names>U</given-names></name><name><surname>Trabetti</surname><given-names>E</given-names></name><name><surname>Malerba</surname><given-names>G</given-names></name><name><surname>Biscuola</surname><given-names>M</given-names></name><name><surname>Girelli</surname><given-names>D</given-names></name><etal/></person-group><year>2007</year><article-title>Gene sequence variations of the platelet P2Y12 receptor are associated with coronary artery disease.</article-title><source>BMC Med Genet</source><volume>8</volume><fpage>59</fpage><pub-id pub-id-type="pmid">17803810</pub-id></citation></ref><ref id="pone.0001462-Cuisset1"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cuisset</surname><given-names>T</given-names></name><name><surname>Frere</surname><given-names>C</given-names></name><name><surname>Quilici</surname><given-names>J</given-names></name><name><surname>Morange</surname><given-names>PE</given-names></name><name><surname>Saut</surname><given-names>N</given-names></name><etal/></person-group><year>2007</year><article-title>Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome.</article-title><source>Thromb Res</source></citation></ref><ref id="pone.0001462-Schettert1"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schettert</surname><given-names>IT</given-names></name><name><surname>Pereira</surname><given-names>AC</given-names></name><name><surname>Lopes</surname><given-names>NH</given-names></name><name><surname>Hueb</surname><given-names>WA</given-names></name><name><surname>Krieger</surname><given-names>JE</given-names></name></person-group><year>2006</year><article-title>Association between platelet P2Y12 haplotype and risk of cardiovascular events in chronic coronary disease.</article-title><source>Thromb Res</source><volume>118</volume><fpage>679</fpage><lpage>683</lpage><pub-id pub-id-type="pmid">16405973</pub-id></citation></ref><ref id="pone.0001462-vonBeckerath1"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>von Beckerath</surname><given-names>N</given-names></name><name><surname>von Beckerath</surname><given-names>O</given-names></name><name><surname>Koch</surname><given-names>W</given-names></name><name><surname>Eichinger</surname><given-names>M</given-names></name><name><surname>Schomig</surname><given-names>A</given-names></name><etal/></person-group><year>2005</year><article-title>P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose.</article-title><source>Blood Coagul Fibrinolysis</source><volume>16</volume><fpage>199</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">15795539</pub-id></citation></ref><ref id="pone.0001462-Lee1"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>DK</given-names></name><name><surname>Nguyen</surname><given-names>T</given-names></name><name><surname>Lynch</surname><given-names>KR</given-names></name><name><surname>Cheng</surname><given-names>R</given-names></name><name><surname>Vanti</surname><given-names>WB</given-names></name><etal/></person-group><year>2001</year><article-title>Discovery and mapping of ten novel G protein-coupled receptor genes.</article-title><source>Gene</source><volume>275</volume><fpage>83</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">11574155</pub-id></citation></ref><ref id="pone.0001462-Criqui1"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Criqui</surname><given-names>MH</given-names></name><name><surname>Langer</surname><given-names>RD</given-names></name><name><surname>Fronek</surname><given-names>A</given-names></name><name><surname>Feigelson</surname><given-names>HS</given-names></name><name><surname>Klauber</surname><given-names>MR</given-names></name><etal/></person-group><year>1992</year><article-title>Mortality over a period of 10 years in patients with peripheral arterial disease.</article-title><source>N Engl J Med</source><volume>326</volume><fpage>381</fpage><lpage>386</lpage><pub-id pub-id-type="pmid">1729621</pub-id></citation></ref><ref id="pone.0001462-McCullough1"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McCullough</surname><given-names>PA</given-names></name></person-group><year>2007</year><article-title>Coronary artery disease.</article-title><source>Clin J Am Soc Nephrol</source><volume>2</volume><fpage>611</fpage><lpage>616</lpage><pub-id pub-id-type="pmid">17699471</pub-id></citation></ref><ref id="pone.0001462-Amisten1"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Amisten</surname><given-names>S</given-names></name><name><surname>Melander</surname><given-names>O</given-names></name><name><surname>Wihlborg</surname><given-names>AK</given-names></name><name><surname>Berglund</surname><given-names>G</given-names></name><name><surname>Erlinge</surname><given-names>D</given-names></name></person-group><year>2006</year><article-title>Increased risk of acute myocardial infarction and elevated levels of C-reactive protein in carriersof the Thr-87 variant of the ATP receptor P2Y11.</article-title><source>Eur Heart J</source></citation></ref><ref id="pone.0001462-Manjer1"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Manjer</surname><given-names>J</given-names></name><name><surname>Carlsson</surname><given-names>S</given-names></name><name><surname>Elmstahl</surname><given-names>S</given-names></name><name><surname>Gullberg</surname><given-names>B</given-names></name><name><surname>Janzon</surname><given-names>L</given-names></name><etal/></person-group><year>2001</year><article-title>The Malmo Diet and Cancer Study: representativity, cancer incidence and mortality in participants and non-participants.</article-title><source>Eur J Cancer Prev</source><volume>10</volume><fpage>489</fpage><lpage>499</lpage><pub-id pub-id-type="pmid">11916347</pub-id></citation></ref><ref id="pone.0001462-OrhoMelander1"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Orho-Melander</surname><given-names>M</given-names></name><name><surname>Klannemark</surname><given-names>M</given-names></name><name><surname>Svensson</surname><given-names>MK</given-names></name><name><surname>Ridderstrale</surname><given-names>M</given-names></name><name><surname>Lindgren</surname><given-names>CM</given-names></name><etal/></person-group><year>2002</year><article-title>Variants in the calpain-10 gene predispose to insulin resistance and elevated free fatty acid levels.</article-title><source>Diabetes</source><volume>51</volume><fpage>2658</fpage><lpage>2664</lpage><pub-id pub-id-type="pmid">12145185</pub-id></citation></ref><ref id="pone.0001462-Barrett1"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Fry</surname><given-names>B</given-names></name><name><surname>Maller</surname><given-names>J</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name></person-group><year>2005</year><article-title>Haploview: analysis and visualization of LD and haplotype maps.</article-title><source>Bioinformatics</source><volume>21</volume><fpage>263</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">15297300</pub-id></citation></ref><ref id="pone.0001462-Skol1"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Skol</surname><given-names>AD</given-names></name><name><surname>Scott</surname><given-names>LJ</given-names></name><name><surname>Abecasis</surname><given-names>GR</given-names></name><name><surname>Boehnke</surname><given-names>M</given-names></name></person-group><year>2006</year><article-title>Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies.</article-title><source>Nat Genet</source><volume>38</volume><fpage>209</fpage><lpage>213</lpage><pub-id pub-id-type="pmid">16415888</pub-id></citation></ref><ref id="pone.0001462-Coade1"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coade</surname><given-names>SB</given-names></name><name><surname>Pearson</surname><given-names>JD</given-names></name></person-group><year>1989</year><article-title>Metabolism of adenine nucleotides in human blood.</article-title><source>Circ Res</source><volume>65</volume><fpage>531</fpage><lpage>537</lpage><pub-id pub-id-type="pmid">2548757</pub-id></citation></ref><ref id="pone.0001462-Bergfeld1"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bergfeld</surname><given-names>GR</given-names></name><name><surname>Forrester</surname><given-names>T</given-names></name></person-group><year>1992</year><article-title>Release of ATP from human erythrocytes in response to a brief period of hypoxia and hypercapnia.</article-title><source>Cardiovasc Res</source><volume>26</volume><fpage>40</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">1325292</pub-id></citation></ref><ref id="pone.0001462-Ramensky1"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ramensky</surname><given-names>V</given-names></name><name><surname>Bork</surname><given-names>P</given-names></name><name><surname>Sunyaev</surname><given-names>S</given-names></name></person-group><year>2002</year><article-title>Human non-synonymous SNPs: server and survey.</article-title><source>Nucleic Acids Res</source><volume>30</volume><fpage>3894</fpage><lpage>3900</lpage><pub-id pub-id-type="pmid">12202775</pub-id></citation></ref><ref id="pone.0001462-Leng1"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leng</surname><given-names>GC</given-names></name><name><surname>Lee</surname><given-names>AJ</given-names></name><name><surname>Fowkes</surname><given-names>FG</given-names></name><name><surname>Whiteman</surname><given-names>M</given-names></name><name><surname>Dunbar</surname><given-names>J</given-names></name><etal/></person-group><year>1996</year><article-title>Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population.</article-title><source>Int J Epidemiol</source><volume>25</volume><fpage>1172</fpage><lpage>1181</lpage><pub-id pub-id-type="pmid">9027521</pub-id></citation></ref><ref id="pone.0001462-Angiolillo1"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Angiolillo</surname><given-names>DJ</given-names></name><name><surname>Fernandez-Ortiz</surname><given-names>A</given-names></name><name><surname>Bernardo</surname><given-names>E</given-names></name><name><surname>Ramirez</surname><given-names>C</given-names></name><name><surname>Cavallari</surname><given-names>U</given-names></name><etal/></person-group><year>2005</year><article-title>Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease.</article-title><source>Thromb Res</source><volume>116</volume><fpage>491</fpage><lpage>497</lpage><pub-id pub-id-type="pmid">16181985</pub-id></citation></ref><ref id="pone.0001462-Hetherington1"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hetherington</surname><given-names>SL</given-names></name><name><surname>Singh</surname><given-names>RK</given-names></name><name><surname>Lodwick</surname><given-names>D</given-names></name><name><surname>Thompson</surname><given-names>JR</given-names></name><name><surname>Goodall</surname><given-names>AH</given-names></name><etal/></person-group><year>2005</year><article-title>Dimorphism in the P2Y1 ADP receptor gene is associated with increased platelet activation response to ADP.</article-title><source>Arterioscler Thromb Vasc Biol</source><volume>25</volume><fpage>252</fpage><lpage>257</lpage><pub-id pub-id-type="pmid">15514209</pub-id></citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>The study has been supported by the Swedish Scientific Research Council, the Swedish Heart and Lung Foundation Lund University Hospital funds and the Vascular Wall program (Lund Medical faculty).</p></fn></fn-group></back></article> 